Pharmacokinetics of Prednisolone at Steady State in Young Patients With Systemic Lupus Erythematosus on Prednisone Therapy: An Open-Label, Single-Dose Study

被引:17
作者
Sagcal-Gironella, Anna Carmela P. [3 ]
Sherwin, Catherine M. T. [1 ,2 ]
Tirona, Rommel G. [4 ]
Rieder, Michael J. [4 ]
Brunner, Hermine I. [3 ,5 ]
Vinks, Alexander A. [1 ,2 ,5 ]
机构
[1] Cincinnati Childrens Hosp, Med Ctr, Div Clin Pharmacol, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp, Med Ctr, PPRU, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp, Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA
[4] Univ Western Ontario, Div Clin Pharmacol, London, ON, Canada
[5] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
关键词
pediatric SLE; pharmacokinetics; prednisolone; prednisone; systemic lupus erythematosus; DISEASE-ACTIVITY INDEX; NEPHROTIC SYNDROME; P-GLYCOPROTEIN; CHILDREN; CORTICOSTEROIDS; GLUCOCORTICOIDS; TRANSPLANTATION; POLYMORPHISMS; DISPOSITION; POPULATION;
D O I
10.1016/j.clinthera.2011.09.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Current prednisone dosing in the treatment of young patients with childhood-onset systemic lupus erythematosus (cSLE) is largely based on achieving balance between therapeutic efficacy and toxicity, with weight-based dosing a common clinical practice. Despite the widespread use of prednisone, few attempts have been made to improve its clinical dosing regimen, and response to prednisone therapy remains variable. Objective: The purpose of this study was to characterize the pharmacokinetic (PK) properties of prednisolone, the metabolite of the prodrug prednisone, in cSLE patients and explore the relationship between PK properties and cSLE disease activity. Methods: Blood samples were taken 1 hour before the morning prednisone dose and at 20, 40, 60, and 90 minutes, and 2, 3, 4, 6, and 9 hours from 8 patients (ages 12-28 years) after an 8-hour fast. The mean weight-adjusted daily prednisone dose, stable for at least 30 days pre-study, was 0.29 mg/kg/d. PK analysis of prednisolone was performed using noncompartmental analysis with WinNonlin. cSLE disease activity was measured using the British Isles Lupus Assessment Group index and Systemic Lupus Erythematosus Disease Activity Index. Results: Mean total prednisolone AUC(0-9), prednisone CL/F at steady state, and half-life were 1094 (range, 467-2404) ng/h/mL, 11 (range, 6.7-13.7) L/hr, and 2.6 (range, 1.3-3.9) hours. Mean total prednisolone AUC(0-9) normalized to prednisone dose by weight was 4361 (range, 1136-9580) ng/h/mL/mg/kg. Mean total prednisolone C(max) normalized to prednisone dose by weight was 1097 (range, 301-2211) ng/mL/mg/kg at 1.84 (range, 0.48-4) hours (T(max)). Patients on prednisone had interindividual variability in prednisolone AUC(0-9) (61% CV) and dose-adjusted AUC(0-9) (58% CV). Conclusions: Interindividual variability in systemic exposure to prednisolone in cSLE patients was observed. (Clin Ther. 2011;33:1524-1536) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:1524 / 1536
页数:13
相关论文
共 50 条
[41]   Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study [J].
Sohn, Winnie ;
Winkle, Peter ;
Neutel, Joel ;
Wu, You ;
Jabari, Freeman ;
Terrio, Caitlin ;
Varrieur, Tracy ;
Wang, Jingying ;
Hellawell, Jennifer .
CLINICAL THERAPEUTICS, 2022, 44 (09) :1237-1247
[42]   Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study [J].
Xianmin Meng ;
Qianqian Wang ;
Shunquan Wu ;
Di Pu ;
Amber Zhang ;
Sun Fang ;
Xuan Zhou ;
Hongzhou Lu .
Rheumatology and Therapy, 2021, 8 :1711-1724
[43]   SINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF SABELUZOLE IN SENILE DEMENTIA OF ALZHEIMER TYPE PATIENTS [J].
DEDEYN, PP ;
VANDEVELDE, V ;
VERSLEGERS, W ;
SAERENS, J ;
PICKUT, BA ;
CLINCKE, B ;
WOESTENBORGHS, R ;
VANPEER, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (06) :661-662
[44]   An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults [J].
Kato, Kota ;
den Adel, Martin ;
Groenendaal-van de Meent, Dorien ;
Ohtsu, Yoshiaki ;
Takada, Akitsugu ;
Katashima, Masataka .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (05) :595-602
[45]   A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients [J].
Gutman, Dikla ;
Hellriegel, Edward ;
Aycardi, Ernesto ;
Bigal, Marcelo E. ;
Kunta, Jeevan ;
Chitra, Rohini ;
Kansagra, Sujay ;
Kidron, Orna Srur ;
Knebel, Helena ;
Linder, Steven ;
Ma, Yuju ;
Pierce, Mark ;
Winner, Paul K. ;
Spiegelstein, Ofer .
HEADACHE, 2016, 56 (08) :1300-1309
[46]   Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study [J].
Fuhr, Rainard ;
Leselbaum, Anne ;
Aubets, Jordi .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (02) :109-117
[47]   Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients [J].
Püchler, K ;
Sierakowski, B ;
Roots, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (04) :363-367
[48]   Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial [J].
Boinpally, Ramesh ;
Jakate, Abhijeet ;
Butler, Matthew ;
Borbridge, Lisa ;
Periclou, Antonia .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07) :726-733
[49]   Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial [J].
Boinpally, Ramesh ;
Lu, Kaifeng .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (07) :857-864
[50]   Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study [J].
Cheng, C. F. ;
Huang, Y. M. ;
Lu, C. H. ;
Hsieh, S. C. ;
Li, K. J. .
LUPUS, 2019, 28 (14) :1699-1704